13F Holdings
中文EN

ACH ACCENDRA HEALTH INC/VA/

Wholesale-Medical, Dental & Hospital Equipment & Supplies · NYSE · SEC CIK 75252 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.0%
TTM net income YoY-195.8%
TTM EPS YoY-195.6%
Revenue 3-yr CAGR-35.4%
Net income 3-yr CAGR—

Margins

Gross margin46.0%
Operating margin0.9%
Net margin-39.8%
FCF margin-10.7%
EBITDA margin8.2%

Returns

ROE-2,037.6%
ROA-29.8%
ROIC (approx.)1.0%
Asset turnover0.75x

Leverage & solvency

Liabilities / assets119.2%
Debt / equity—
Current ratio0.49x
Interest coverage0.22x

Cash quality & payout

Operating cash flow / net income0.11x
Accruals ratio-26.5%
Payout ratio—
Capex / revenue6.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.76B$2.68B$2.55B$9.96B$9.79B
Cost of revenue$1.47B$1.40B$1.34B$8.13B$8.27B
Gross profit$1.29B$2.22B$2.13B$1.83B$1.51B
R&D expense—$13.00M$13.00M$12.00M$12.10M
SG&A expense$1.07B$1.08B$1.00B$1.55B$1.08B
Operating income$27.46M-$217.73M$133.23M$142.91M$368.47M
Interest expense$107.18M$107.57M$116.77M$128.89M$48.09M
Pretax income-$101.95M-$329.88M$15.27M$10.89M$276.75M
Income tax$729,000$20.85M$6.36M-$11.50M$55.16M
Net income-$1.10B-$362.69M-$41.30M$22.39M$221.59M
EBITDA$241.98M-$36.45M$343.60M$371.58M$459.09M
EPS (basic)-14.31-4.73-0.540.303.05
EPS (diluted)-14.31-4.73-0.530.292.94
Dividends declared per share————0.01
Weighted avg. shares (diluted)76.90M76.74M77.37M76.22M75.49M
Balance sheet
Cash & equivalents$281.99M$27.57M$272.92M$86.19M$72.03M
Inventory$74.44M$67.58M$1.11B$1.33B$1.50B
Current assets$547.87M$2.02B$2.10B$2.30B$2.32B
PP&E, net$256.16M$249.28M$543.97M$578.27M$317.24M
Goodwill$1.23B$1.23B$1.64B$1.64B$390.19M
Intangibles$136.47M$210.06M$361.83M$445.04M$209.75M
Total assets$2.45B$4.66B$5.09B$5.39B$3.54B
Current liabilities$947.08M$1.85B$1.89B$1.57B$1.34B
Short-term debt$250.00M$42.87M$206.90M$17.91M—
Long-term debt$1.80B$1.80B$1.89B$2.48B$947.54M
Total debt$2.05B$1.84B$2.10B$2.50B$947.54M
Total liabilities$2.91B$4.07B$4.17B$4.44B$2.60B
Shareholders' equity-$460.98M$586.36M$945.30M$966.74M$938.50M
Net debt$1.77B$1.81B$1.82B$2.41B$875.50M
Shares outstanding76.39M77.20M76.55M76.28M75.43M
Cash flow statement
Operating cash flow-$101.79M$161.50M$740.71M$325.01M$124.18M
Capital expenditure$190.96M$170.29M$172.38M$158.09M$40.98M
Free cash flow-$292.75M-$8.79M$568.34M$166.92M$83.19M
Investing cash flow$144.42M-$116.53M-$137.25M-$1.80B-$53.63M
Financing cash flow$188.08M-$267.60M-$417.33M$1.50B-$129.48M
Depreciation & amortization$214.52M$181.28M$210.37M$228.67M$90.62M
Stock-based compensation$12.87M$16.64M$14.39M$20.99M$25.02M
Dividends paid——$0$0$731,000
Share buybacks$10.18M————

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.